Takeda Oncology
Whitney Benson is a seasoned administrative professional with extensive experience in executive support and corporate communications. Currently serving as the Executive Assistant to the President of Global Oncology at Takeda Oncology since January 2024, Whitney previously held multiple roles at Xilio Therapeutics, Inc., including Corporate Communications Manager and Senior Executive Assistant to the President & CEO. Previous experience includes serving as Head of US Administration at Oncopeptides AB, as well as various executive assistant roles at EMD Serono, Inc., LPL Financial, Ruesch International, Geller & Company, Deutsche Bank, and Harvard University Kennedy School of Government. Whitney holds a Bachelor of Science degree in Biology & Immunology from High Point University and has studied at Université Paris-Sorbonne.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.